Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
- PMID: 29343509
- DOI: 10.1136/annrheumdis-2017-212478
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
Abstract
Objective: To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).
Methods: 321 patients were randomised (1:1:1:1) to placebo or tregalizumab 25, 100 or 200 mg once-weekly subcutaneously in addition to MTX treatment. Responders at week 12 continued the same treatment, and non-responders at week 12 were escalated to the next higher tregalizumab dose level or re-randomised from placebo to active treatment. After 24 weeks, patients could continue treatment with tregalizumab for 24 weeks (extension phase). The primary endpoint was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Safety and biological activity were monitored through week 48.
Results: At week 12, ACR20 response rates were not statistically significantly different between placebo and any of the tregalizumab doses. Tregalizumab injections were well tolerated; most adverse events were mild to moderate and comparable among treatment and placebo groups. Biological activity was shown by dose-dependent CD4 downmodulation.
Conclusion: Treatment with tregalizumab did not show significant clinical efficacy in patients with active RA compared with placebo but resulted in the expected biological effect on CD4 modulation. Tregalizumab was generally well tolerated, and no new safety findings were identified.
Trial registration number: NCT01999192; Results.
Keywords: Dmards (biologic); autoimmune diseases; rheumatoid arthritis; t cells.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: RFvV has received research support and grants from AbbVie, BMS, GSK, Pfizer and UCB and has been a consultant and received honoraria from AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Novartis, Pfizer, Roche and UCB. ECK has received research funding from Abbott Laboratories, Amgen, AstraZeneca, BMS, Roche, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis and UCB; has served as a consultant/advisory board member for Abbott Laboratories, AstraZeneca, Biotest, BMS, Crescendo, Roche, Genentech, Janssen, Lilly, Merck, Pfizer, and UCB; and has received speaker honoraria from Amgen, Abbott Laboratories, Astrazeneca, BMS Canada, Roche, Janssen, Pfizer, Sanofi Genzyme, and UCB. VS has been a consultant for Biotest. CP-T has received support from Abbvie, BMS, Roche, UCB, Janssen, Amgen, AstraZeneca, Pfizer, GSK, Ely Lilly, Sanofi, Celltrion, Vertex and Novo-Nordisk. FB has received research grants/support from Roche, Pfizer and Chugai and has been a consultant for AbbVie, Biotest, BMS, Janssen, Lilly, Pfizer, UCB, Novartis, Genzyme, AstraZeneca, MSD/Merck. DZ, FR, RW, LK, RS, XZ, SA, BD and AW-D are or were employees of Biotest.
Comment in
-
Therapy: Arming the regulators - new strategies to treat autoimmunity.Nat Rev Rheumatol. 2018 Mar 21;14(4):188-189. doi: 10.1038/nrrheum.2018.50. Nat Rev Rheumatol. 2018. PMID: 29559717 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
